%0 Journal Article
%T Organ at Risk Doses during High Dose Rate Intracavitary Brachytherapy for Cervical Cancer: A Dosimetric Study
%A N. V. Vinin
%A Joneetha Jones
%A V. T. Ajas
%A Geetha Muttath
%A C. A. Suja
%A E. K. Nabeel Yahiya
%A P. N. Shoaib Nawaz
%A Arun P. Narendran
%A P. Shimjith
%J International Journal of Medical Physics,Clinical Engineering and Radiation Oncology
%P 472-478
%@ 2168-5444
%D 2018
%I Scientific Research Publishing
%R 10.4236/ijmpcero.2018.74040
%X <span style=\"font-family:Verdana;\"><b><span style=\"font-family:Verdana;\">Background</span></b></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><b><span style=\"font-family:Verdana;\">: </span></b></span></span><span><span><span style=\"font-family:&quot;\"><span style=\"font-family:Verdana;\">Treatment
of Cervical cancer includes a combination of exter</span><span style=\"font-family:Verdana;\">nal beam radiotherapy (EBRT) with intracavitary brachytherapy</span></span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">(ICBT).
ICBT helps to boost radiation dose to primary disease. Organs like rectum,</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">bladder,</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">sigmoid
and small bowel lie</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">close to the cervix region and these organs receive dose from EBRT as
well as ICBT and we want to know the dose to these </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">organ
at risk (OAR).</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><b><span style=\"font-family:Verdana;\">Materials &amp; Methods</span></b></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><b><span style=\"font-family:Verdana;\">: </span></b></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">Dosimetric
details of 174 ICBT applications done in 58 patients were retrospectively
analysed. All patients received EBRT dose of 50.4 Gy in 28 fractions. All
patients had ICBT, three sessions with 7 Gy prescribed to point A.</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span
%K Intracavitary Brachytherapy
%K Carcinoma Cervix
%K Organ at Risk
%K High Dose Rate Brachytherapy
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=87770